News of Note—Bavarian Nordic, universal flu vaccine and more

In this week's news of note, Bavarian Nordic presented more phase 2 RSV vaccine data. (Pixabay)

> Bavarian Nordic presented additional phase 2 data for its RSV candidate showing antibodies were present in participants' nasal mucosa, suggesting the vaccine can protect at the source of infection. Release

> The National Institute of Allergy and Infectious Diseases presented a strategic plan to develop a universal flu vaccine, stressing that collaboration between industry, academia and others will be important in the effort. Release

> Oxford University spinout Oxford Vacmedix raised $12.5 million to advance two cancer vaccines into human testing. Endpoints News article

> Sinovac has sued top shareholders over what it says was an illegal takeover attempt. Law360 article

Suggested Articles

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

The partnership aims to make the production of vaccines that use adenovirus as vectors more cost-effective and contamination-free.

GSK's Shingrix has nabbed a huge chunk of the U.S. shingles-shot market, just five months after it was approved by the FDA.